InMode (NASDAQ:INMD) (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.
InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.
The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America. In addition to product deployment, InMode provides training, clinical support and marketing services to practitioners to facilitate the adoption of its platforms.
Founded in the late 2000s, InMode completed its initial public offering in 2019. Managed by an experienced leadership team with backgrounds in medical device development, its ongoing research and development efforts focus on expanding its aesthetic treatment portfolio and exploring new clinical applications of its energy-based platforms.
